Title Category Credit Event date Costsort descending
Non-Alcoholic Fatty Liver Disease
  • Disease Management
  • AMA - Physicians
  • ANCC - Nurses
  • Attendance - General Attendance
$0.00 This activity will discuss the prevalence, diagnosis and factors that contribute to the development of non-alcoholic fatty liver disease (NAFLD). Best practices for the treatment of individuals with NAFLD will also be discussed.
CMS HEDIS and Stars Pharmacy Overview—Medication Adherence, Statin Use in Patients and More
  • Disease Management
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • ASWB - Social Workers
$0.00 Participants in this activity will learn how CMS measures medication adherence, its role in patient qualification status, impact on claims algorithms, and potential caveats of these determinations. Strategies to address common barriers to medication adherence will be discussed, along with best practices that may improve adherence. In addition, the five measures included in the 2021 Medicare Part D star ratings, including those regarding medication adherence for diabetes, hypertension, cholesterol, as well as statin use in persons with diabetes, will be reviewed.
Duchenne Muscular Dystrophy: Utilizing Personalized Treatments and Addressing Health
  • Disease Management
  • Health Equity
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • CCMC - General - Case Managers
  • ASWB - Social Workers
$0.00 This activity will discuss emerging therapies for DMD and the importance of incorporating a personalized interprofessional care plan, along with the role of health disparities and how these impacts access to care and outcomes for these individuals.
Sickle Cell Disease: Understanding Gene Therapy and Addressing Health Disparities
  • Disease Management
  • Health Equity
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • CCMC - General - Case Managers
  • ASWB - Social Workers
$0.00 This activity will discuss the effects and complications of SCD, the prevalence of SCD in different racial and ethnic groups and the role of gene therapy as treatment. Health disparities and challenges in accessing specialized care will also be addressed.
Health in the Midst of Adversity: Cardiovascular Risk and Resilience in the Black Community
  • Disease Management
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • ASWB - Social Workers
$0.00 This activity will provide learners with current data surrounding multiple factors that predispose Black patients to either increased risk or resilience for CVD and will examine the risk- and resilience-associated diversity within this population with the goal of improving cardiovascular health for these individuals.
Cystic Fibrosis: Utilizing Personalized Treatments and Addressing Health Disparities
  • Disease Management
  • Health Equity
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • CCMC - General - Case Managers
  • ASWB - Social Workers
$0.00 During this activity, presenters will discuss CF and the different genetic etiologies and examine how an individual’s genetic profile can be utilized to develop a personalized treatment plan. The role that an informed interprofessional health care team can play in improved disease outcomes will also be examined. 
Threading the Needle: Practical Considerations in the Modern, Evidence-based Management of Type 2 Diabetes
  • Disease Management
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • ASWB - Social Workers
$0.00 This activity will assist learners in identifying optimal lifestyle and behavioral changes that can impact disease development and progression in their patients and will discuss practical strategies and forms of support that HCPs can offer to assist patients in setting healthy lifestyle goals. Learners will examine how appropriate prescribing decisions must be based on a comparative analysis of diabetes medications and will also review disease etiology and biological changes seen during disease progression. Lastly, the presenter will discuss policy and system changes that can best assist in integrating evidence into daily practice for the purpose of maximizing health in individuals with T2D. 
Optimal Care—Combining Evidence and Technology to Drive Quality and Eliminate Low-Value Care
  • Disease Management
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • ASWB - Social Workers
$0.00 This activity will provide learners with successful approaches to address the issues of wasted and harmful care in order to decrease unnecessary expenditures and improve patient outcomes.
Gene Therapy: Transitioning from Proof of Principle to Practical Treatments
  • Disease Management
  • Transplantation
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • CCMC - General - Case Managers
  • ASWB - Social Workers
$0.00 This activity will explore the current and future application of gene therapy.
Diabetic Kidney Disease: Improving Outcomes and Reducing Costs
  • Disease Management
  • ACPE - Pharmacists
  • ACPE - Pharmacy Technicians
  • AMA - Physicians
  • ANCC - Nurses
  • APA - Psychologists
  • Attendance - General Attendance
  • ASWB - Social Workers
$0.00 This activity will present HCPs with the information necessary to evaluate kidney health in individuals with type 2 diabetes mellitus (T2DM) and will discuss CKD risk stratification, including interpretation of albuminuria levels and estimated glomerular filtration rate (eGFR). Interventions that can reduce progression of disease, likelihood of hospitalization and costs will be identified, and recent data about effective treatment regimens and their indications for improving outcomes will be examined. Additionally, early strategies to decrease the risk for CVD and ESRD in these individuals will be defined, with a review of the pathophysiology of progression of these disorders. 

Pages